Boehringer Ingelheim - Top 15 Pharma R&D Budgets

R&D budget: $3.03B (€2.21B)
Change over 08: +5%
Income spent on R&D: 17.4%

Big Pharma R&D budgets usually dwarf the estimated revenue expected from their experimental therapies. But Boehringer beat the spread just weeks ago when it delivered on its long-awaited approval of Pradaxa, a blood-thinner expected to go on to earn billions in annual sales revenue.

Boehringer has been active on the partnering side of the business, but it was a latecomer to the corporate venture game. Back in March the company announced plans to invest $137 million in biotech companies as it sent its scout teams around the world to find the most promising new developers on the scene.

Boehringer's top three disease focuses: Cardiovascular, respiratory and cerebrovascular diseases.

Boehringer Ingelheim - Top 15 Pharma R&D Budgets

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.